Earnings Feed
Start Free
Vor Biopharma Inc.·4

Apr 15, 5:29 PM ET

RA Capital Healthcare Fund LP 4

Research Summary

AI-generated summary

Updated

Vor Biopharma (VOR) 10% Holder RA Capital Sells $11.9M Shares

What Happened
RA Capital Management, L.P. (a reported 10% holder and investment manager for RA Capital Healthcare Fund) sold a total of 737,989 shares of Vor Biopharma (VOR) in open‑market or private sales across April 13–15, 2026. The three disposals were: 530,610 shares at a weighted average of $16.15 (≈ $8,569,352) on 2026‑04‑13; 153,735 shares at a weighted average of $15.97 (≈ $2,455,148) on 2026‑04‑14; and 53,644 shares at a weighted average of $16.01 (≈ $858,840) on 2026‑04‑15. Total proceeds across the three dates were approximately $11.88 million. These were sales (not purchases), which are commonly routine portfolio transactions for institutional holders.

Key Details

  • Transaction dates and reported weighted averages:
    • 2026‑04‑13: 530,610 shares @ $16.15 (weighted avg; reported range $15.94–$16.32) — F1
    • 2026‑04‑14: 153,735 shares @ $15.97 (weighted avg; reported range $15.75–$16.17) — F4
    • 2026‑04‑15: 53,644 shares @ $16.01 (weighted avg; reported range $16.005–$16.10) — F5
  • Aggregate sold: 737,989 shares for roughly $11.88M in proceeds.
  • Holdings after the transactions: not specified in the provided filing details.
  • Footnotes / ownership structure:
    • Shares were held directly by RA Capital Healthcare Fund, L.P. (the Fund) — F3.
    • RA Capital Management, L.P. is the Fund’s investment manager; the Adviser, its GP, and named individuals disclaim beneficial ownership except for any pecuniary interest — F2.
    • Filing notes weighted‑average pricing and provides price ranges for the multiple transaction executions (F1, F4, F5); the filer offers to provide per‑trade price breakdowns on request.
  • Board connection: Dr. Andrew Levin, a partner/managing director of the Adviser, serves on Vor’s board (reported in Remarks).
  • Timeliness: Filing date Apr 15, 2026 for transactions through Apr 15 appears timely under standard Form 4 reporting windows.

Context

  • This Form 4 reports institutional disposals by a 10% holder (an investment fund/manager relationship), not an executive exercising options or receiving awards. Institutional sales often reflect portfolio rebalancing and do not by themselves indicate management sentiment about the company’s prospects.
  • No purchases, option exercises, gifts, or tax‑withholding events were reported in this filing.